Congestive heart failure (CHF) remains the most common reason for hospitalization in the
United States for people aged 65 years and older, with more than 1 million patients admitted …

The renin–angiotensin–aldosterone system (RAAS), an important regulator of blood
pressure and mediator of hypertension-related complications, is a prime target for …

Angiotensin II (ANG II) contributes to hypertension, cardiac hypertrophy, fibrosis, and
dysfunction; however, it is difficult to separate the cardiac effect of ANG II from its …

The renin–angiotensin system (RAS) is a prime target for cardiovascular drug therapy.
Inhibition of the RAS lowers blood pressure and confers protection against cardiovascular …

Hypertension is the main risk factor for left ventricular hypertrophy and development of
diastolic heart failure. There is no yet treatment, which can effectively reduce mortality in …

BACKGROUND: There are increasing evidences of endothelial dysfunction in migraine. The
ACE-inhibitors have previously been shown to be effective in migraine prophylaxis …

Introduction The renoprotective effect of renin-angiotensin (RAS) blockers (angiotensin
converting enzyme inhibitors and angiotensin receptor blockers) has been questioned in …

The renin-angiotensin system, in both its circulating and local tissue roles, is intertwined with
multiple other regulatory and signalling mechanisms in various tissues and organ systems. It …

Recent clinical trials have demonstrated that combination therapy with renin-angiotensin
system inhibitors plus calcium channel blockers (CCBs) elicits beneficial effects on …

The World's Leading Experts Provide all the'Essentials' Needed to Manage Patients in the
Office and on the Ward! Nearly 17% of adults in the United States have Chronic Kidney …